<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351195</url>
  </required_header>
  <id_info>
    <org_study_id>etoxel-01-2005</org_study_id>
    <nct_id>NCT00351195</nct_id>
  </id_info>
  <brief_title>Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Morten Ladekarl, MD, DMSc., Dept. of Oncology, Århus Sygehus, Århus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <brief_summary>
    <textblock>
      Various cytotoxic agents have been evaluated in advanced hepatocellular carcinoma, but&#xD;
      response rates have been low with significant toxicity, most often due to parenchymal liver&#xD;
      disease. The three agents etoposide, oxaliplatin and capecitabine each has sparse efficacy as&#xD;
      single agents, but the combination may act synergistically with an acceptable toxicity&#xD;
      profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      Open phase II study.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      Response rate for the combination of etoposide, oxaliplatin and capecitabine given every 3&#xD;
      weeks on an outpatient basis.&#xD;
&#xD;
      Secondary endpoint are safety, time to progression and survival&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Etoposide are administered intravenously 100 mg/m2 on day 1 and orally 200 mg/m2 on days 2&#xD;
      and 3.&#xD;
&#xD;
      Capecitabine (Xeloda) are administered 1000 mg/m2 twice daily with 12 hours interval for two&#xD;
      weeks and one week off&#xD;
&#xD;
      Oxaliplatin are administered intravenously 100 mg/m2 on day 1 in each cycle as a 2 hours&#xD;
      infusion.&#xD;
&#xD;
      One cycle is 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Did not meet the criteria for continuation to second stage&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified intra- or extrahepatic inoperable hepatocellular carcinoma or&#xD;
             hyperdense liver lesion at computed tomography and concurrent elevated&#xD;
             alpha-feto-protein &gt; 400 ng/ml&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Normal bone marrow function (neutrophiles &gt; 1,5 x 109/l and platelets &gt; 100 x 109/l)&#xD;
&#xD;
          -  Bilirubin &lt; 2 x UNL&#xD;
&#xD;
          -  Transaminases &lt; 3 x UNL&#xD;
&#xD;
          -  Normal renal function, Cr-EDTA clearance &gt; 50 ml/min&#xD;
&#xD;
          -  No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion&#xD;
&#xD;
          -  No uncontrolled, severe concurrent medical disease&#xD;
&#xD;
          -  Fertile women must have a negative pregnancy test&#xD;
&#xD;
          -  Fertile women must use adequate contraceptives during and 3 months after trial&#xD;
             exposure&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion&#xD;
&#xD;
          -  Experimental therapy &lt; 8 weeks prior to inclusion&#xD;
&#xD;
          -  Known DPD-deficiency&#xD;
&#xD;
          -  Known neuropathy&#xD;
&#xD;
          -  Uncontrolled, severe concurrent medical disease&#xD;
&#xD;
          -  Prior malignancy during the last 5 years, except for non-melanoma skin cancer and&#xD;
             carcinoma in situ cervix uteri.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Århus Sygehus, Dept. of Oncology</name>
      <address>
        <city>Århus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <last_update_submitted>August 25, 2008</last_update_submitted>
  <last_update_submitted_qc>August 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

